News & Events about Intellia Therapeutics Inc.
JMP Securities downgraded shares of Intellia Therapeutics (NASDAQ:NTLA Get Rating) from an outperform rating to a market perform rating in a research report sent to investors on Thursday morning, Marketbeat.com reports. Several other brokerages have also recently issued reports on NTLA. Wells Fargo...
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA Get Rating) have been given an average rating of Moderate Buy by the twenty research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold ...
Innovation Passport provides entry to the U.K.s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in ...
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies,announced today the pricing of an underwritten public offering of 6...